{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:32Z","timestamp":1789958852679,"version":"4.0.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019492","name":"National Natural Science Foundation of China-China Academy of General Technology Joint Fund for Basic Research","doi-asserted-by":"publisher","award":["31822030, 31771458, 81873440"],"award-info":[{"award-number":["31822030, 31771458, 81873440"]}],"id":[{"id":"10.13039\/501100019492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Most relapsed chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) discontinuation are in a chronic phase and could achieve remission through restarting the TKI treatment. Here we reported a case of sudden lymphoid blast crisis after 67 months of TKI discontinuation and depicted the patient by DNA and RNA sequencing to investigate intrinsic molecular features. The mutations of TGFBR2 and PCNT and the dysregulations of TGF-\u03b2 and other pathways might accelerate the B cell transformation, which may serve as a blast crisis risk indicator of CML. Single-cell transcriptome data revealed that several clusters of immature B cells and late pro-B cells presented clone evolution during the treatment. After failing multiple lines of TKIs, conditioning chemotherapies and chimeric antigen receptor T cells (CAR-T) targeting CD19 and CD22 were performed to achieve remission. In conclusion, we report the first case of a CML patient with sudden lymphoid blast crisis after a long treatment-free remission and additional gene abnormalities other than BCR-ABL1 might participate in the progression, which need to be closely monitored, and CAR-T could be a solution to the chemoresistant progression.<\/jats:p>","DOI":"10.3389\/fonc.2021.739871","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T05:48:20Z","timestamp":1632203300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI"],"prefix":"10.3389","volume":"11","author":[{"given":"Ya-Ru","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Yuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2020.04.016","article-title":"Transcriptome Profiling Reveals the High Incidence of Hnrnpa1 Exon 8 Inclusion in Chronic Myeloid Leukemia","volume":"24","author":"Li","year":"2020","journal-title":"J Adv Res"},{"key":"B3","article-title":"Whole Exome Sequencing of Chronic Myeloid Leukemia Patients","volume":"45","author":"Sabri","year":"2016","journal-title":"Iran J Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E3928","DOI":"10.3390\/ijms19123928","article-title":"Tgf\u03b2 Superfamily Members as Regulators of B Cell Development and Function-Implications for Autoimmunity","volume":"19","author":"Tamayo","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902880","article-title":"ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy","volume":"7","author":"Miao","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and Efficacy of Imatinib Cessation for CML Patients With Stable Undetectable Minimal Residual Disease: Results From the TWISTER Study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of Major Molecular Response as a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124408","article-title":"Prognostication of Molecular Relapses After Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2g-TKI Study Update","volume":"134","author":"Rea","year":"2019","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/HS9.0000000000000157","article-title":"Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop","volume":"2","author":"Papalexandri","year":"2018","journal-title":"HemaSphere"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-Term Benefits and Risks of Frontline Nilotinib vs Imatinib for Chronic Myeloid Leukemia in Chronic Phase: 5-Year Update of the Randomized ENESTnd Trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1002\/ctm2.317","article-title":"A Folate Receptor 3 SNP Promotes Mitochondria-Induced Clonogenicity of CML Leukemia Cells: Implications for Treatment Free Remission","volume":"11","author":"Shen","year":"2021","journal-title":"Clin Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0647-x","article-title":"Lineage of Measurable Residual Disease in Patients With Chronic Myeloid Leukemia in Treatment-Free Remission","volume":"34","author":"Pagani","year":"2020","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and Safety of CAR19\/22 T-Cell Cocktail Therapy in Patients With Refractory\/Relapsed B-Cell Malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.739871\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T05:48:23Z","timestamp":1632203303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.739871\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":14,"alternative-id":["10.3389\/fonc.2021.739871"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.739871","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"article-number":"739871"}}